Farms.com Home   News

Farmers Looking To Resume Corn Harvest

Farmers have been slowly getting back into the grain corn harvest this week.
 
Morgan Cott is an agronomist with the Manitoba Corn Growers Association.
 
"If they can get out there and get some work done then by all means they're going to do it because the corn just basically is not going to be drying very fast right now, so if you can get some done now and slowly plug away at it, then I don't think that there's too much harm in doing that rather than waiting a month."
 
Cott says the corn crop seemed to have escaped the brunt of the winter storm.
 
"Just from what I'm seeing in the last few days, it hasn't done as much damage to the actual plants by pushing them over or making anything drop that shouldn't drop," she commented. "I think it's mostly just the tops of the plants that are infected. Aside from being in a lot of moisture."
 
Cott says there is reports of mold in the corn but some of that is not particularly harmful to the plant. She notes the concern now is that mold will spread with the high degree of moisture in the fields and air.
Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.